G0S2 knockout activated the type I interferon signaling pathway, enhanced CD8+ T cell functionality, and synergized with anti-PD-1 therapy, resulting in suppressed tumor growth and prolonged survival in vivo. Here, G0S2 is linked to neoplasm.